Gilead Sciences (GILD) Cash from Investing Activities (2009 - 2026)

Gilead Sciences (GILD) has reported Cash from Investing Activities for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $1.8 billion, up 526.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 57.39% YoY), and the FY2025 annual result was -$4.8 billion, down 38.97% from the prior year.
• Cash from Investing Activities was $1.8 billion for Q1 2026 at Gilead Sciences, up from -$1.8 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.8 billion in Q1 2026 and troughed at -$2.2 billion in Q1 2024.
• Average Cash from Investing Activities over 5 years is -$659.0 million, with a median of -$483.0 million recorded in 2023.
• Year-over-year, Cash from Investing Activities plunged 715.56% in 2025 and jumped 526.51% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$375.0 million in 2022, then slumped by 93.87% to -$727.0 million in 2023, then soared by 69.05% to -$225.0 million in 2024, then slumped by 715.56% to -$1.8 billion in 2025, then jumped by 196.46% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $1.8 billion in Q1 2026, -$1.8 billion in Q4 2025, and -$427.0 million in Q3 2025.